Abstract
You have accessJournal of UrologyProstate Cancer: Localized: Ablative Therapy (MP46)1 Sep 2021MP46-08 A MULTI-INSTITUTIONAL STUDY OF MRI/ULTRASOUND FUSION IMAGING AND BIOPSY IN COMBINATION WITH NANOPARTICLE DIRECTED FOCAL THERAPY FOR ABLATION OF PROSTATE TISSUE Arvin George, Steven Canfield, Joshua Jue, Sara Lewis, Matthew Davenport, Varaha Tammisetti, Mahir Maruf, Leonardo Borregalaes, Jon Schwartz, Naomi Halas, and Ardeshir Rastinehad Arvin GeorgeArvin George More articles by this author , Steven CanfieldSteven Canfield More articles by this author , Joshua JueJoshua Jue More articles by this author , Sara LewisSara Lewis More articles by this author , Matthew DavenportMatthew Davenport More articles by this author , Varaha TammisettiVaraha Tammisetti More articles by this author , Mahir MarufMahir Maruf More articles by this author , Leonardo BorregalaesLeonardo Borregalaes More articles by this author , Jon SchwartzJon Schwartz More articles by this author , Naomi HalasNaomi Halas More articles by this author , and Ardeshir RastinehadArdeshir Rastinehad More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002067.08AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Focal therapy is currently being evaluated as an alternative to whole gland therapy in men with low to intermediate risk prostate cancer. There are several different modalities that are utilized to focally treat prostate tissue/tumors, however most modalities have some degree of non-target ablation. We report the final results of the first in human, nanoparticle directed focal ablation of prostate tissue using MRI/Ultrasound fusion guidance. METHODS: This is an open-label, multi-center study of men with low to intermediate risk localized prostate cancer treated with a single-dose of AuroLase therapy and the focal excitation of neoplastic prostate tissue via nanoparticle directed excitation. Up to two focal areas of prostate cancer confirmed by MRI/Ultrasound guided biopsy with no disease appreciated outside of the region of each lesion were included. Efficacy of focal prostate tissue ablation was assessed by MRI/Ultrasound guided biopsy and serum PSA at 3 and 12 months. RESULTS: 45 men were enrolled in the study. 44 men completed infusion and ablation, with a total of 45 lesions included in the study. The mean PSA at baseline was 9.6, which decreased to 3.6 at 3 months and 4.9 at 12 months, p<0.01. 33 lesions (73.3%) were negative and 12 lesions (26.7%) were positive on 3 month and 12 month postablation biopsy, p=0.54. 1 patient underwent salvage cryotherapy at 12 months. Serum PSA, PSA velocity, change in PSA, and proportional change in PSA at baseline, 3 months, and 12 months were not significant predictors of lesion biopsy result. CONCLUSIONS: Ultra-focal ablation of neoplastic prostate tissue via nanoparticle directed excitation results in a 73.3% lesion ablation success rate confirmed by an end of study MRI/Ultrasound fusion guided biopsy of the treated lesion and standard template. Source of Funding: Sponsored by Nanospectra Biosciences, Inc. and Philips Healthcare © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e816-e816 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Arvin George More articles by this author Steven Canfield More articles by this author Joshua Jue More articles by this author Sara Lewis More articles by this author Matthew Davenport More articles by this author Varaha Tammisetti More articles by this author Mahir Maruf More articles by this author Leonardo Borregalaes More articles by this author Jon Schwartz More articles by this author Naomi Halas More articles by this author Ardeshir Rastinehad More articles by this author Expand All Advertisement Loading ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.